1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Tennessee >
  6. Harrow Acquires Melt

M&A Deal Summary

Harrow Acquires Melt

On September 26, 2025, Harrow acquired life science company Melt

Acquisition Highlights
  • This is Harrow’s 7th transaction in the Life Science sector.
  • This is Harrow’s 8th transaction in the United States.
  • This is Harrow’s 1st transaction in Tennessee.

M&A Deal Summary
Date 2025-09-26
Target Melt
Sector Life Science
Buyer(s) Harrow
Deal Type Add-on Acquisition

Target

Melt

Brentwood, Tennessee, United States
Melt is a clinical-stage pharmaceutical company focused on developing proprietary non-IV, non-opioid, sedation, and analgesia therapeutics for human medical procedures in the hospital, outpatient, and in-office settings. The company intends to seek regulatory approval through the FDA’s 505(b)(2) regulatory pathway for its proprietary, patented small-molecule product candidates, where possible. Its core intellectual property is the subject of multiple granted patents in North America, Europe, Asia, and the Middle East. Melt is based in Brentwood, Tennessee.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Harrow

Nashville, Tennessee, United States
Category Company
Founded 1998
Sector Life Science
Employees382
Revenue 200M USD (2024)
DESCRIPTION

Harrow is a developer, producer, and dispenser of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Harrow was founded in 1998 and is based in Nashville, Tennessee.

DEAL STATS #
Overall 9 of 9
Sector: Life Science M&A 7 of 7
Type: Add-on Acquisition M&A Deals 3 of 3
State: Tennessee M&A 1 of 1
Country: United States M&A 8 of 8
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-18 Santen - Branded Ophthalmic Portfolio

Osaka, Japan

Santen’s Branded Ophthalmic Portfolio Includes U.S. and Canadian commercial rights to Flarex, natacyn, tobradex st, verkazia, zerviate, and non-prescription brands freshkote and cationorm plus.

Buy -
Mergr

Solution for

Product

Company

Legal